NextCure Stock Price

-0.76 (-5.81%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
NextCure Inc NXTC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.76 -5.81% 12.31 20:00:00
Open Price Low Price High Price Close Price Prev Close
12.22 12.04 12.69 12.31 13.07
Bid Price Ask Price Spread News
11.60 13.50 1.90 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,524 269,650 $ 12.27 $ 3,308,273 458,329 7.91 - 54.95
Last Trade Time Type Quantity Stock Price Currency
16:57:07 1 $ 12.02 USD

NextCure Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 339.18M 27.55M 25.80M $ 6.35M $ -6.00M -1.60 -10.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

NextCure News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NXTC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week11.6013.4010.9012.38200,6160.716.12%
1 Month11.4013.409.880211.11366,5460.917.98%
3 Months11.6013.749.4910.94401,3410.716.12%
6 Months9.4913.747.919.94539,2602.8229.72%
1 Year52.8754.957.9117.06449,644-40.56-76.72%
3 Years15.55109.007.9126.77375,162-3.24-20.84%
5 Years15.55109.007.9126.77375,162-3.24-20.84%

NextCure Description

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The company's product candidate, NC318, is an immunomedicine against an immunomodulatory receptor called Siglec-15, or S15.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.